Unique Ingredient Identifier 1Q73Q2JULR is listed as a unspecified ingredient
| NCIT | C62075 |
| RXCUI | 253204 |
UNII 1Q73Q2JULR SODIUM CITRATE, UNSPECIFIED FORM is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| INTRAVENOUS | INJECTION | 0.37 % |
| ORAL | LIQUID | 12.5 mg/10mL |
| ORAL | SUSPENSION | 21.91 mg/1mL |
| AN,INFILTRATION | INJECTION | 0.04 % |
| AURICULAR (OTIC) | SOLUTION | 2 % |
| AURICULAR (OTIC) | SUSPENSION | NA |
| EPIDURAL | INJECTION | 2.2 % |
| IM - IV | INJECTABLE | 1.35 % |
| IM - IV | INJECTION | 40 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 3.5 % |
| IM - IV | SOLUTION | 0.025 % |
| IM - IV - SC | INJECTABLE | 0.23 % |
| IM - IV - SC | INJECTION | 0.94 % |
| IM - SC | INJECTION | 0.23 % |
| INHALATION | INHALANT | NA |
| INHALATION | SOLUTION | 0.6 % |
| INHALATION | SUSPENSION, FOR INHALATION | 0.05 % |
| INTRA-ARTERIAL | INJECTION | 0.3 % |
| INTRA-ARTICULAR | INJECTION | 2.2 % |
| INTRACARDIAC | INJECTION | 0.8 % |
| INTRACAVITARY | INJECTION | 0.15 % |
| INTRACAVITARY | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.005 % |
| INTRALESIONAL | INJECTION | 1 % |
| INTRAMUSCULAR | INJECTABLE | 0.435 % |
| INTRAMUSCULAR | INJECTION | 4 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | 4.62 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.74 % |
| INTRAMUSCULAR | SOLUTION, INJECTION | 1.47 % |
| INTRAOCULAR | SOLUTION | 0.4 % |
| INTRAPERITONEAL | INJECTION | 2.2 % |
| INTRAPLEURAL | INJECTION | ADJPH |
| INTRAPLEURAL | POWDER, FOR INJECTION SOLUTION | 4.62 % |
| INTRASYNOVIAL | INJECTION | 1 % |
| INTRATHECAL | INJECTION | ADJPH |
| INTRATHECAL | POWDER, FOR INJECTION SOLUTION | 4.62 % |
| INTRATRACHEAL | SUSPENSION | NA |
| INTRAUTERINE | SOLUTION | 0.32 % |
| INTRAVASCULAR | INJECTION | 0.32 % |
| INTRAVENOUS | INFUSION | ADJPH |
| INTRAVENOUS | INJECTABLE | 20 % |
| INTRAVENOUS | INJECTION | 1.64 MG/1ML |
| INTRAVENOUS | INJECTION | 0.6 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 0.16 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 16.35 % |
| INTRAVENOUS | SOLUTION | 0.83 % |
| IONTOPHORESIS | DRUG DELIVERY SYSTEM | 2.2 MG |
| IRRIGATION | INJECTION | 2.2 % |
| IV(INFUSION) | INJECTABLE | 0.547 % |
| IV(INFUSION) | INJECTION | 40 % |
| IV(INFUSION) | INJECTION | 30 MG/100ML |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 8 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 14 % |
| IV(INFUSION) | SOLUTION, CONCENTRATE | 2.4 % |
| IV(INFUSION) | SOLUTION, INJECTION | 0.6 % |
| NASAL | GEL | NA |
| NASAL | SOLUTION | 0.7 % |
| NASAL | SPRAY | 44 % |
| NASAL | SPRAY, METERED | 95.9 UG/SPRAY |
| NERVE BLOCK | INJECTION | 0.04 % |
| OPHTHALMIC | POWDER, FOR SOLUTION | 0.17 % |
| OPHTHALMIC | SOLUTION | 2.2 % |
| OPHTHALMIC | SOLUTION, DROPS | 2 % |
| OPHTHALMIC | SUSPENSION | 0.3 % |
| OPHTHALMIC | SUSPENSION, DROPS | 0.45 % |
| ORAL | CAPSULE | 1 MG |
| ORAL | CONCENTRATE | 5.07 MG/1ML |
| ORAL | DROPS | 100 MG/5ML |
| ORAL | EMULSION | NA |
| ORAL | GRANULE | 210.63 MG/5ML |
| ORAL | GRANULE, FOR RECONSTITUTION | 0.7 MG |
| ORAL | GRANULE, FOR SUSPENSION | 15 MG |
| ORAL | LIQUID | ADJPH |
| ORAL | POWDER, FOR ORAL SUSPENSION | 40 MG/5ML |
| ORAL | POWDER, FOR RECONSTITUTION | 2 MG/5ML |
| ORAL | POWDER, FOR SOLUTION | 2942 MG/PACKET |
| ORAL | POWDER, FOR SUSPENSION | 37.5 MG/5ML |
| ORAL | SOLUTION | 1567.5 MG/75ML |
| ORAL | SOLUTION | ADJ PH |
| ORAL | SOLUTION, CONCENTRATE | 0.5 MG/1ML |
| ORAL | SOLUTION, ELIXIR | 22.5 MG/5ML |
| ORAL | SOLUTION, LIQUID | 7.09 MG/1ML |
| ORAL | SUSPENSION | 7800 MG/5ML |
| ORAL | SUSPENSION, EXTENDED RELEASE | 13 MG/5ML |
| ORAL | SUSPENSION, LIQUID | 0.9 MG/5ML |
| ORAL | SUSPENSION, SUSTAINED ACTION | 23.5 MG/1PKT |
| ORAL | SYRUP | 25 MG/5ML |
| ORAL | TABLET | 275 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 300 MG |
| ORAL | TABLET, COATED | 19 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 82 MG |
| ORAL | TABLET, EXTENDED RELEASE | 110 MG |
| ORAL | TABLET, FILM COATED | 200 MG |
| RECTAL | SOLUTION | NA |
| RESPIRATORY (INHALATION) | POWDER, FOR INHALATION | 0.14 % |
| RESPIRATORY (INHALATION) | SUSPENSION, FOR INHALATION | 1 MG/2ML |
| SOFT TISSUE | INJECTION | 1 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.74 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 1.47 % |
| SUBLINGUAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL | 3.52 MG |
| TOPICAL | CREAM | 0.12 %W/W |
| TOPICAL | CREAM | 0.12 %W/W |
| TOPICAL | EMULSION, CREAM | 0.25 %W/W |
| TOPICAL | EMULSION, CREAM | 0.12 %W/W |
| TOPICAL | EMULSION, LOTION | 0.08 %W/W |
| TOPICAL | LOTION | 0.32 %W/W |
| TOPICAL | LOTION | 0.08 %W/W |
| TOPICAL | SHAMPOO | 2.6 %W/W |
| TOPICAL | SOLUTION | 1 MG/1ML |
| TOPICAL | SOLUTION | 0.1 %W/V |
| TOPICAL | SOLUTION, DROPS | 0.29 %W/V |
| TRANSDERMAL | DRUG DELIVERY SYSTEM | 2.2 MG |
| URETERAL | SOLUTION | NA |
| VAGINAL | SPONGE | 7.6 MG |